최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.28 no.3, 2018년, pp.204 - 215
신혜연 (덕성여자대학교 약학대학) , 천부순 (인제대학교 약학대학 인제약학연구소)
Background: In this systematic review and meta-analysis, the effect of metformin on weight loss was assessed to determine whether metformin should be recommended for the prevention or treatment of weight gain in patients receiving antipsychotic medication for the treatment of schizophrenia or schizo...
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
조현병이란? | 조현병(schizophrenia)은 망상, 환각, 무욕증(avolition), 정서적 둔마(affective flattening), 상황에 맞지 않는 행위 및 긴장증적인 행동을 보이며 비논리적인 언어를 사용하고 집중력, 기억력, 수행능력의 부족 등으로 인해 직장생활, 대인관계, 자기관리 등의 기능이 현저히 저하되는 정신질환이다.1) 조현병의 치료에는 약물요법이 주축이며 대부분의 경우 항정신병 약물치료 없이는 정신사회적 재활프로그램을 효과적으로 수행할 수 없으므로 항정신병 약물은 조현병의 약물치료에서 핵심이 된다. | |
항정신병 약물이 2세대 항정신병 약물에서는 약물 사용을 중단하는 주요 이유는 무엇인가? | 3) 일단 조현병으로 진단되면 1세대 항정신병약물 혹은 clozapine을 제외한 2세대 항정신병 약물의 사용이 권장되지만 1세대 항정신병 약물을 사용하는 경우 추체외로계 증상(extrapyramidal symptom, EPS)이 발생할 위험이 있어 2세대 항정신병 약물이 더 선호된다. Clozapine의 경우 조현병의 치료에 우수한 효과를 발휘함에도 불구하고 과립백혈구감소증의 부작용으로 인해 1차선택약이 되지 못하고 타 약물로 치료에 실패한 경우에 사용된다.4) 조현병의 약물치료에 있어 항정신병 약물이 근간이 되지만 2세대 항정신병 약물에 의한 체중증가와 대사장애는 약물사용을 중단하는 주요원인이 되기도 하여 olanzapine과 clozapine의 경우 약 9%, quetiapine과 ziprasidone의 경우는 3~4%, risperidone은 약 2%에 이르는 환자가 약물치료를 중단했던 것으로 보고되었다. | |
조현병의 약물치료에서 핵심이 되는 약물은 무엇인가? | 조현병(schizophrenia)은 망상, 환각, 무욕증(avolition), 정서적 둔마(affective flattening), 상황에 맞지 않는 행위 및 긴장증적인 행동을 보이며 비논리적인 언어를 사용하고 집중력, 기억력, 수행능력의 부족 등으로 인해 직장생활, 대인관계, 자기관리 등의 기능이 현저히 저하되는 정신질환이다.1) 조현병의 치료에는 약물요법이 주축이며 대부분의 경우 항정신병 약물치료 없이는 정신사회적 재활프로그램을 효과적으로 수행할 수 없으므로 항정신병 약물은 조현병의 약물치료에서 핵심이 된다.2) 조현병의 치료를 위한 항정신병 약물로 국내에서는 현재 1세대 항정신병약물인 chlorpromazine, haloperidol과 2세대 항정신병약물인 aripiprazole, clozapine, olanzapine, paliperidone, risperidone, quetiapine, ziprasidone, zotepine 등이 사용되고 있다. |
American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM- $5^{TM}$ 5th ed. Arlington, VA, US: American Psychiatric Publishing, Inc., 2013
Crismon M. L, Argo T, Buckley P. Schizophrenia, In: DiPiro J, Talbert R, Yee G et al., Pharmacotherapy: a pathophysiologic approach, 9th ed. New York: McGraw-Hill Education, 2013:1022-8
BIT Druginfo. Available from https://www.druginfo.co.kr. Accessed June 25, 2018.
Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry(WFSBP) guidelines for the biological treatment of schizophrenia. Part 3: Update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation 2015;16:142-70.
Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23.
Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100(1):3-16.
Hasnain M, Vieweg WV, Fredrickson SK. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs 2010;24(3):193-206.
Pringsheim T, Kelly M, Urness D, et al. Physical Health and Drug Safety in Individuals with Schizophrenia. Can J Psychiatry 2017;62(9):673-83.
Scottish Intercollegiate Guidelines Network. Management of schizophrenia. SIGN Publication 131. Edinburgh (Scotland): SIGN 2013.
Chamberlain JJ, Herman WH, Leal S, et al. Pharmacologic therapy for type 2 diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med 2017; 166(8):572-8.
Professional Practice Committee: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018;41(Suppl 1):S3.
Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990;13(6):696-704.
Schultes B, Oltmanns KM, Kern W, et al. Modulation of hunger by plasma glucose and metformin. J Clin Endocrinol Metab 2003; 88(3):1133-41.
Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes 2013;121(1):27-31.
Kusaka I, Nagasaka S, Horie H, et al. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab 2008;10(11):1039-46.
Aubert G, Mansuy V, Voirol M-J, et al. The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism 2011;60(3):327-34.
Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes 2014;21(5):323-9.
Zheng W, Li XB, Tang YL, et al. Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol 2015;35(5):499-509.
Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 Available from http://handbook-5-1.cochrane.org/. Accessed July 25, 2018.
Xuan C, Zhang BB, Li M, et al. No association between APOE ${\varepsilon}$ 4 allele and multiple sclerosis susceptibility: a meta-analysis from 5472 cases and 4727 controls. J Neurol Sci 2011;308(1-2):110-6.
Choi YY, Sohn HS, Shin HT. Clinical benefits of self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: A systematic Review and Meta-analysis. Kor J Clin Pharm 2010; 20(3):183-92.
Baptista T, Martinez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry 2006;51(3):192-6.
Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007;93(1-3):99-108.
Arman S, Sadramely MR, Nadi M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 2008;29(8):1130-4.
Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008;165(3):352-8.
Carrizo E, Fernandez V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009;113(1):19-26.
Tao F. Efficacy of metformin for treatment of olanzapine-induced weight gain in patients with first-episode schizophrenia. Xiandai Shiyong Yixue 2012;24:58-9, 97.
Wang M, Tong JH, Zhu G, et al. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res 2012;138(1):54-7.
Chen CH, Huang MC, Kao CF, et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013;74(5):e424-30.
Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013;170(9):1032-40.
de Silva VA, Dayabandara M, Wijesundara H, et al. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. J Psychopharmacol 2015; 29(12):1255-61.
Hebrani P, Manteghi AA, Behdani F, et al. Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder. J Res Med Sci 2015;20(4):364-71.
Chiu CC, Lu ML, Huang MC, et al. Effects of Low Dose Metformin on Metabolic Traits in Clozapine-Treated Schizophrenia Patients: An Exploratory Twelve-Week Randomized, Double-Blind, Placebo-Controlled Study. PLoS One 2016;11(12):e0168347.
Rado J, von Ammon Cavanaugh S. A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population. J Clin Psychopharmacol 2016;36(2):163-8.
Wu RR, Zhang FY, Gao KM, et al. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebocontrolled trials. Mol Psychiatry 2016;21(11):1537-44.
Centers for disease control and prevention. Overweight & Obesity. Available from https://www.cdc.gov/obesity/adult/defining.html. Accessed August 1, 2018.
St Jeor ST, Brunner RL, Harrington ME, et al. A classification system to evaluate weight maintainers, gainers, and losers. J Am Diet Assoc 1997;97(5):481-8.
Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001;9 Suppl 4:326S-334S.
Korean Academy of Medical Sciences. Evidence-based Recommendations for Hypertension in Primary Care 2014.
Brown JD, Buscemi J, Milsom V, et al. Effects on cardiovascular risk factors of weight losses limited to 5-10. Transl Behav Med 2016; 6(3):339-46.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.